Table 2.
Baseline characteristics of the validation cohort.
| Total | Males | Females | p | |
|---|---|---|---|---|
| n | 704 | 387 | 317 | |
| Age (years) | 54 (20) | 52 (22) | 57 (16) | 0.004 |
| BMI (kg/m2) | 37.8 (13.14) | 37.8 (15.86) | 37.4 (9.15) | 0.155 |
| FGF21 (ng/L) | 198.84 (207.29) | 184.73 (196.47) | 212.98 (224.69) | 0.005 |
| T2D (yes/no) | 341/371 | 156/228 | 180/137 | 2.00 × 10 − 5 |
| Smoker (yes/no) | 114/518 | 62/295 | 51/218 | 0.608 |
Continuous normally distributed data are shown as mean with standard deviation. FGF21 is shown as median with interquartile rage; for T2D and smokers, total numbers are shown. Group differences were calculated by Mann-Whitney-U test (continuous parameters) or Chi-square-test (discrete variables: T2D and smokers). p-values presented comparison of males vs. females. A p-value 0.05 was considered to be significant and was highlighted in bold. n = number of subjects; p = p-value; BMI = body-mass index; T2D = type 2 diabetes; FGF21 = fibroblast growth factor-21.